Lipocine Inc. Establishes Clinical Feasibility of Once-a-Day Ziprasidone  
11/11/2008 9:58:50 AM

SALT LAKE CITY--(BUSINESS WIRE)--Lipocine Inc. (, a specialty pharmaceutical company that uses clinically validated proprietary technologies to address key unmet drug delivery and therapeutic needs, today announced the successful completion of a clinical study that establishes feasibility of the first once-a-day dosing product for Ziprasidone, a leading treatment for schizophrenia and bipolar disorder.